Home News About us Comitato scientifico Iscriviti Utenti Etica Contenuti Guida Faq Stage Contatti ☰
Logo Pharmamedix
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Paliperidone

Invega, Xeplion

Bibliografia - Quali fonti bibliografiche per Paliperidone?

  1. Agenzia italiana del farmaco - AIFA, Nota informativa, 2013, 2 settembre.

  2. Boom S. et al., J. Clin. Pharmacol., 2009, 49 (11), 1318.

  3. Boom S. et al., Int. J. Clin. Pharmacol. Ther., 2009a, 47 (10), 606.

  4. Canuso C.M. et al., J. Clin. Psychiatry, 2010, 71 (5), 587.

  5. Canuso C.M. et al., J. Clin. Psychopharmacol., 2010a, 30 (5), 487.

  6. Chang D.F., Campbell J.R., J. Cataract Refract. Surg., 2005, 31 (4), 664.

  7. Chang J.P. et al., Prog. Neuropsychopharmacol. Biol. Psychiatry, 2010, 34 (2), 418.

  8. Citrome L., Expert. Opin. Drug Metab. Toxicol., 2012, 8 (7), 873.

  9. Davidson M. et al., Schizophrenia Research, 2007, 93, 117.

  10. Ema - European Medicine Agency, Invega - Invega, Riassunto della caratteristiche del prodotto, 2012 disponibile online http://emea.europa.eu/humandocs/Humans/EPAR/invega/invega.htm

  11. Ema - European Medicine Agency, Invega - Xeplion, Riassunto della caratteristiche del prodotto, 2012a disponibile online http://emea.europa.eu/humandocs/Humans/EPAR/xeplion/xeplion.htm

  12. Emsley R. et al., Int. Clin. Psychopharmacol., 2008, 23 (6), 343.

  13. Food and Drug Administration - FDA, Invega Trinza - Label information, 2015, 18 maggio disponibile online http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory#labelinfo

  14. Gill J.S. et al., Turk. Psikiyatri Derg., 2010, 21 (4), 331.

  15. Gopal S. et al., Int. Clin. Psychopharmacol., 2010, 25 (5), 247.2010

  16. Harrington C.A., English C., Int. Clin. Psychopharmacol., 2010, 25 (6), 334.

  17. Janssen Pharmaceuticals, Invega (paliperidone) Extended-Release Tablets, 2011 disponibile online www.janssencns.com/invega-prescribing-information (ultimo accesso 20 febbraio 2013).

  18. Joo S.W et al., Clin. Psychopharmacol. Neurosci., 2022, 20 (4), 675.

  19. Kramer M. et al., J. Clin. Psychopharmacol., 2007, 27 (1), 6.

  20. Kane J. et al., Schizophrenia Research, 2007, 90, 147.

  21. Kramer M. et al., J. Clin. Psychopharmacol., 2007, 27 (1), 6.2007

  22. Levine M. et al., Ann. Emerg. Med., 2011, 58 (1), 80.

  23. Liang C.S. et al., J. Clin. Psychopharmacol., 2012, 32 (1), 128.

  24. Luthringer R. et al., Int. Clin. Psychopharmacol., 2007, 22 (5), 299.

  25. Marder S.R. et al., Biol. Psychiatry, 2007, 62, 1363.

  26. Medicines and Healthcare Regulatory Agence - MHRA, Antipsychotic drugs, 2012 www.mhra.gov.uk/Safetyinformation/Generalsafetyinformationandadvice/Product-specificinformationandadvice/Product-specificinformationandadvice-A-F/Antipsychoticdrugs/index.htm#l4

  27. Meltzer H.Y. et al., J. Clin. Psychiatry, 2008, 69, 817.

  28. Nussbaum A., Stroup T.S., Cochrane Database of Systemic Review 2008, Issue 2.

  29. Pottegard A. et al., Br. J. Clin. Pharmacol., 2018, 84 (9), 2152.

  30. Pringle E., Packard R., J. Cataract Refract. Surg., 2005, 31 (12), 2240.

  31. Santami M.N. et al., Clin. Pharmacokinet., 2009, 48 (9), 585.

  32. Singh J. et al., Biol. Psychiatry, 2011, 70 (12), 1179.

  33. Taipale H. et al., Lancet Psychiatry, 2021, 8 (10), 883.

  34. Vermeir M. et al., Drug Metab. Dispos., 2008, 36 (4), 769.

  35. Vieta E. et al., Bipolar Disord., 2010, 12 (3), 230.

  36. Tzimos A. et al., Am. J. Geriatr. Psychiatry, 2008, 16 (1), 31.

  37. Wang S. et al., Clin. Drug Investig., 2012, 32 (8), 497.